KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $577.9 million.

  • Royalty Pharma's Other Non-Current Liabilities rose 468369.21% to $577.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $577.9 million, marking a year-over-year increase of 468369.21%. This contributed to the annual value of $577.9 million for FY2025, which is 468369.21% up from last year.
  • Latest data reveals that Royalty Pharma reported Other Non-Current Liabilities of $577.9 million as of Q4 2025, which was up 468369.21% from $502.9 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Other Non-Current Liabilities registered a high of $577.9 million during Q4 2025, and its lowest value of $900000.0 during Q4 2023.
  • For the 4-year period, Royalty Pharma's Other Non-Current Liabilities averaged around $113.5 million, with its median value being $12.1 million (2024).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 8054.92% in 2023, then surged by 891322.58% in 2025.
  • Royalty Pharma's Other Non-Current Liabilities (Quarter) stood at $2.5 million in 2022, then tumbled by 64.0% to $900000.0 in 2023, then soared by 1242.22% to $12.1 million in 2024, then skyrocketed by 4683.69% to $577.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $577.9 million for Q4 2025, versus $502.9 million for Q3 2025 and $467.1 million for Q2 2025.